poisar

Stocks · News reference

Braveheart Bio Announces Upcoming Presentations and Investor Webinar for BHB-1893

Fiscal.ai

Braveheart Bio, Inc. will present late-breaking 52-week extension data for its cardiac myosin inhibitor, BHB-1893, at the American Heart Association Scientific Sessions 2026 and host a related investor webinar.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading